0000868278
2016-01-01
2016-03-31
0000868278
2016-03-31
0000868278
2015-12-31
0000868278
PRPH:EstimatedFutureSalesReturnMember
2016-03-31
0000868278
PRPH:CooperativeIncentiveMember
2016-03-31
0000868278
PRPH:EstimatedFutureSalesReturnMember
2015-12-31
0000868278
PRPH:CooperativeIncentiveMember
2015-12-31
0000868278
us-gaap:EmploymentContractsMember
2016-03-31
0000868278
PRPH:GodfreySettlementAgreementMember
2016-03-31
0000868278
us-gaap:DomesticCountryMember
2016-01-01
2016-03-31
0000868278
us-gaap:StateAndLocalJurisdictionMember
2016-01-01
2016-03-31
0000868278
us-gaap:CommonStockMember
2015-12-31
0000868278
us-gaap:AdditionalPaidInCapitalMember
2015-12-31
0000868278
us-gaap:RetainedEarningsMember
2015-12-31
0000868278
us-gaap:TreasuryStockMember
2015-12-31
0000868278
PRPH:TwoThousandTenEquityCompensationPlanMember
2015-05-05
0000868278
PRPH:TwoThousandFifteenEquityLineOfCreditMember
PRPH:DutchessMember
2015-07-01
2015-07-30
0000868278
2016-05-13
0000868278
us-gaap:SecuredDebtMember
2015-12-10
2015-12-11
0000868278
us-gaap:SecuredDebtMember
2015-12-11
0000868278
2015-12-11
0000868278
2015-12-10
2015-12-11
0000868278
PRPH:GodfreySettlementAgreementMember
2012-12-20
0000868278
us-gaap:DebtMember
2016-03-31
0000868278
PRPH:NineteeenNinetySevenEquityCompensationPlanMember
2016-03-31
0000868278
2015-01-01
2015-03-31
0000868278
PRPH:FutureProductDevelopmentMember
2016-03-31
0000868278
us-gaap:CommonStockMember
2016-01-01
2016-03-31
0000868278
us-gaap:CommonStockMember
2016-03-31
0000868278
us-gaap:AdditionalPaidInCapitalMember
2016-01-01
2016-03-31
0000868278
us-gaap:AdditionalPaidInCapitalMember
2016-03-31
0000868278
us-gaap:RetainedEarningsMember
2016-01-01
2016-03-31
0000868278
us-gaap:RetainedEarningsMember
2016-03-31
0000868278
us-gaap:TreasuryStockMember
2016-01-01
2016-03-31
0000868278
us-gaap:TreasuryStockMember
2016-03-31
0000868278
2014-12-31
0000868278
2015-03-31
0000868278
us-gaap:BuildingImprovementsMember
us-gaap:MinimumMember
2016-01-01
2016-03-31
0000868278
us-gaap:BuildingImprovementsMember
us-gaap:MaximumMember
2016-01-01
2016-03-31
0000868278
us-gaap:MinimumMember
us-gaap:MachineryAndEquipmentMember
2016-01-01
2016-03-31
0000868278
us-gaap:MachineryAndEquipmentMember
us-gaap:MaximumMember
2016-01-01
2016-03-31
0000868278
us-gaap:FurnitureAndFixturesMember
2016-01-01
2016-03-31
0000868278
PRPH:ComputerSoftwareIntangibleCAssetMember
2016-01-01
2016-03-31
0000868278
PRPH:StockholderRightsPlanMember
2016-01-01
2016-03-31
0000868278
PRPH:TwoThousandFifteenEquityLineOfCreditMember
PRPH:DutchessMember
2016-01-01
2016-03-31
0000868278
PRPH:TwoThousandFifteenEquityLineOfCreditMember
PRPH:DutchessMember
2016-03-31
0000868278
PRPH:TwoThousandTenEquityCompensationPlanMember
2016-03-31
0000868278
PRPH:TwoThosandTenDirectorsEquityCompensationPlanMember
2015-03-31
0000868278
PRPH:TwoThousandTenEquityCompensationPlanMember
2016-01-01
2016-03-31
0000868278
2010-03-22
0000868278
PRPH:GodfreySettlementAgreementMember
2016-03-31
0000868278
PRPH:GodfreySettlementAgreementMember
2015-12-31
0000868278
PRPH:StockholderRightsPlanMember
2016-03-31
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
10-Q
false
2016-03-31
Q1
ProPhase Labs, Inc.
0000868278
--12-31
Smaller Reporting Company
PRPH
30742000
30742000
7494000
8829000
13000
56377000
-16819000
-30742000
13000
56378000
-18155000
-30742000
476000
501000
44000
83000
1500000
445000
1400000
786000
3100000
3100000
4815000
4708000
0.0005
0.0005
50000000
50000000
9232817
9232817
2500000
900000
425000
20000
24159
147808
-1336000
-1380000
-1336000
Expire beginning in Fiscal 2020 through 2034.
Expire beginning in Fiscal 2020 through 2034
-1336000
-1380000
17081
15892
-1336000
-1380000
17081
15892
17080776
17080776
1000
1000
P10Y
P39Y
P3Y
P7Y
P5Y
P3Y
0.50
0.50
17080776
0.15
0.50
2024-06-18
3200000
1713000
1713000
26313593
26313593
2450000
1.35
45
0.0005
0.0005
1000000
1000000
2457000
1664000
366000
2926000
5021000
2500000
2500000
752000
1700000
1000
34000
1416000
1303000
299000
530000
2357000
2498000
869000
769000
100000
2525000
1025000
1500000
512000
512000
3906000
2306000
100000
1500000
-0.08
-0.09
5370000
5860000
2431000
2198000
2939000
3662000
2598000
2812000
1539000
2021000
86000
208000
4223000
5041000
-1284000
-1379000
52000
1000
-1336000
-1380000
500000
The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Common Stock during the one trading day immediately following our put notice. We have the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to us; however, in the event Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).
0.0499
-0.08
-0.09
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have estimated
future minimum obligations over the next five years, including the remainder of Fiscal 2016, as follows (in thousands):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal Year</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employment Contracts</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Godfrey Settlement Agreement</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Note</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 16%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 21%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">769</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">869</font></td>
<td style="width: 1%; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,025</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,525</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">512</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">512</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,306</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,906</font></td>
<td style="line-height: 115%"> </td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b></b></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation
of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing
operations, is as follows (in thousands, except per share amounts):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three Months Ended March 31, 2016</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three Months Ended March 31, 2015</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Loss</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">EPS</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Loss</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">EPS</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Basic</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="width: 28%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">loss per share</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,336</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,081</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,380</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,892</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.09</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dilutives:</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Diluted loss per share</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,336</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,081</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,380</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,892</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.09</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>
2016
1003000
2132000
-397000
-906000
-315000
-453000
572000
564000
-259000
-15000
-1312000
-2368000
1000
34000
5000
-210000
-37000
5000
210000
42000
793000
2095000
3000000
1500000
17000
51000
56000
100000
100000
0.12
0.0325
14000
28000
2017-06-15
0.143
52000
-0.08
-0.09
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Note 1 – Organization and Business </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ProPhase Labs, Inc.
(“we”, “us” or the “Company”), was initially organized in Nevada in July 1989. Effective June
18, 2015, we changed our state of incorporation from the State of Nevada to the State of Delaware. We are a manufacturer, marketer
and distributor of a diversified range of homeopathic and health care products that are offered to the general public. We are also
engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along
with supplement, personal care and cosmeceutical products.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary business
is the manufacture, distribution, marketing and sale of OTC health care and cold remedy products to consumers through national
chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE<sup>Ò </sup>and our principal product
is Cold-EEZE<sup>Ò</sup> cold remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity
of symptoms of the common cold. In addition to Cold-EEZE<sup>®</sup> cold remedy lozenges, we market and distribute non-lozenge
forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE<sup>®</sup> cold remedy QuickMelts<sup>® </sup>and (ii)
Cold-EEZE<sup>®</sup> cold remedy Oral Spray. Each of these Cold-EEZE<sup>®</sup> QuickMelts<sup>® </sup>products are
based on our proprietary zinc gluconate formulation in combination with certain natural (i) immune system support, (ii) energy,
(iii) sleep and relaxation, and/or (iv) cold and flu symptom relieving active ingredients. In Fiscal 2015, we introduced three
new Cold-EEZE<sup>®</sup> product line extensions: (i) a Cold-EEZE<sup>®</sup> Multi-Symptom Relief for Cold and Flu lozenge,
(ii) a Cold-EEZE<sup>®</sup> Daytime and Nighttime Multi-Symptom Relief in liquid form for each of adults and children, and
(iii) Cold-EEZE<sup>Ò </sup>Natural Allergy Relief caplets for indoor and outdoor allergies. Shipments for these three new
Cold-EEZE<sup>®</sup> product line extensions began in the third quarter of Fiscal 2015. We also manufacture, market and distribute
organic cough drops and a Vitamin C supplement, and perform contract manufacturing services of cough drop and other OTC cold remedy
products for third parties.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use a December
31 year-end for financial reporting purposes. References herein to “Fiscal 2016” shall mean the fiscal year ended December
31, 2016 and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated.
The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company,
together with its subsidiaries and consolidated variable interest entities unless the context otherwise requires.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Note 2 – Summary of Significant Accounting Policies</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited condensed
consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial
statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements
and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with
accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed
consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated
financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31,
2015. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated
results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the
three months ended March 31, 2016 are not necessarily indicative of operating results that may be achieved over the course of the
full year.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Seasonality of the Business</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our net sales are
derived principally from our OTC heath care and cold remedy products. Currently, our sales are influenced by and subject to fluctuations
in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity
of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold
rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher
levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products
during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer
demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production
scheduling, inventory management and marketing programs to optimize consumer purchases.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the three months
ended March 31, 2016 and 2015, our net sales were principally related to domestic markets.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Use of Estimates</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation
of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and
assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include
the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible
assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising.
When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales
Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These
estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant
at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments
on a quarterly basis. Actual results could differ from those estimates.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary product,
Cold-EEZE<sup>Ò </sup>cold remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically
proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns
and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii)
promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels
at major customers and third-party consumption data. In addition to Cold-EEZE<sup>®</sup> cold remedy lozenges, we market and
distribute a variety of Cold-EEZE<sup>®</sup> cold remedy QuickMelts<sup>®</sup>, a Cold-EEZE<sup>® </sup>cold remedy
Oral Spray, a Cold-EEZE<sup>Ò </sup>Natural Allergy Relief caplets and Cold-EEZE<sup>®</sup> Daytime and Nighttime Multi-Symptom
Relief in a liquid form. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement. Each of the
Cold-EEZE<sup>®</sup> cold remedy Oral Spray and QuickMelts<sup>®</sup> products, Cold-EEZE<sup>Ò </sup>Natural
Allergy Relief caplets, Cold-EEZE<sup>®</sup> liquid forms and organic lozenge products carry shelf-life expiration dates for
which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales
allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis,
and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences
that could affect the expected provisions relative to net sales for the period presented.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Cash Equivalents</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider all
highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents
include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the
short-term maturity of these investments.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Inventory Valuation </i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Inventory is valued
at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost
and the market value and appropriate valuation adjustments are established. At March 31, 2016 and December 31, 2015, the financial
statements include adjustments to reduce inventory for excess or obsolete inventory of $476,000 and $501,000, respectively. The
components of inventory are as follows (in thousands):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2016</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2015</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 28%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,416</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 28%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,303</font></td>
<td style="width: 1%; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Work in process</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">299</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">530</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,357</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,498</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,072</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,331</font></td>
<td style="line-height: 115%"> </td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Property, Plant and Equipment</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property, plant
and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes.
Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements -
ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures
– five years.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of Risks</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future revenues,
costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity
together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC
and other personal care products in order to compete on a national level and/or international level.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is
subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC health care
and cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration
(“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial instruments
that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts
receivable.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain cash
and cash equivalents with certain major financial institutions. As of March 31, 2016, our cash balance was $2.5 million and our
bank balance was $2.5 million. Of the total bank balance, $752,000 was covered by federal depository insurance and $1.7 million
was uninsured at March 31, 2016.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Trade accounts receivable
potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate
purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s
financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large
national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit
risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other
conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s
financial condition, payment patterns, balance due to us and other factors, we did not offset our account receivable with an allowance
for bad debt at March 31, 2016 and December 31, 2015.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Long-lived Assets</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We review our carrying
value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount
of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum
of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount,
if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based
on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future
cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value
utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing
costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition;
and general economic and business conditions, among other factors.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fair value is based
on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier
fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs
such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either
directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore
requiring an entity to develop its own assumptions.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i> </i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Instruments
</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents,
accounts receivable, accounts payable, accrued expenses and notes payable are reflected in the Condensed Consolidated Financial
Statements at carrying value which approximates fair value.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Revenue Recognition</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales are recognized
at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts
and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns
and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer
and consumer demand when evaluating the adequacy of the sales returns and other allowances.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our return policy
accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their
designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns
must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due
to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns
for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue
a product provided that the customer will have the right to return only such items that it purchased directly from us. We will
not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept
return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers
who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the
customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product
only, also by way of an exchange. We do not have any significant product exchange history.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">  </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31,
2016 and December 31, 2015, we included a provision for sales allowances of $44,000 and $83,000, respectively, which are reported
as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2016 included
(i) $1.5 million for estimated future sales returns and (ii) $445,000 for cooperative incentive promotion costs. As of December
31, 2015, accrued advertising and other allowances included (i) $1.4 million for estimated future sales returns and (ii) $786,000
million for cooperative incentive promotion costs.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Advertising and Incentive Promotions</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Advertising and
incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense
is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions
and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part
of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2016 and 2015 were
$3.1 million and $3.1 million, respectively. Included in prepaid expenses and other current assets was $120,000 and $854,000 at
March 31, 2016 and December 31, 2015, respectively, relating to prepaid advertising and promotion expenses.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Shipping and Handling </i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Product sales carry
shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all
cases, costs related to this revenue are recorded in cost of sales.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Stock Based Compensation</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recognize all
share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements
based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model.
The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with
the vesting period.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock and stock
options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees
and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable
during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March
31, 2016 and 2015, we charged to operations $1,000 and $34,000, respectively, for share-based compensation expense for the aggregate
fair value of stock grants issued and vested stock options earned.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Research and Development</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2016
and 2015 were $86,000 and $208,000, respectively. Research and development costs are principally related to new product development
initiatives and costs associated with our OTC health care and cold remedy products.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Income Taxes</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize the asset
and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of
events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally
consider all expected future events other than enactments of changes in the tax law or rates. Until we have sufficient taxable
income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant
and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize a two-step
approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by
determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on
audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as
the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties
related to income taxes will be recorded as interest or administrative expense, respectively.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of our
continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not
recorded a liability for unrecognized tax benefits.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recently Issued Accounting Standards</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the
Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers”,
on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers
as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing
and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective
approach or cumulative effect adjustment approach to implement the standard. As amended by ASU No. 2015-14 issued in August 2015,
this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2017, with early adoption
permitted. We are currently assessing the impact of this update, and believe that its adoption will not have a material impact
on our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2014,
the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”.<i>
</i>The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting
period, an entity’s management should evaluate whether there are conditions or events that raise substantial doubt about
the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued
(or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in
this update are effective for the annual reporting period beginning after December 15, 2016 and for annual periods and interim
periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our
consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2015, the
FASB issued ASU No. 2015-11 “Simplifying the Measurement of Inventory” which requires an entity to measure inventory
balances at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged
for inventory measured using LIFO or the retail inventory method. The amendments in this update are effective for the annual period
ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently assessing the impact of
this update, and believe that its adoption on January 1, 2017 will not have a material impact on our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016,
the FASB issued ASU No. 2016-02, Leases. The new standard will require most leases to be recognized on the balance sheet which
will increase reported assets and liabilities. Lessor accounting remains substantially similar to current guidance. The new standard
is effective for annual and interim periods in fiscal years beginning after December 15, 2018, which for us is the first quarter
of fiscal 2019 and mandates a modified retrospective transition method. We are currently assessing the impact of this update, and
believe that its adoption will not have a material impact on our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2016, the
FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects
of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory
tax withholding requirements, as well as classification in the statement of cash flows. ASU No. 2016-09 is effective for fiscal
years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for financial
statements that have not already been issued. We are currently assessing the impact that this ASU will have on our consolidated
financial position, results of operation and cash flows.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 – Secured Promissory
Notes and Other Obligations </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Secured Promissory Notes</u></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 11,
2015, we executed two Subscription Agreements (the “Subscription Agreements”) with the investors named therein (the
“Investors”) providing for the purchase of 12% Secured Promissory Notes – Series A (“ Notes”) in
the aggregate principal amount of up to $3.0 million and warrants to purchase shares of our Common Stock (the “Warrants”).</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notes in the amount
of $1,500,000 and 51,000 Warrants, at an exercise price of $1.35 per share, which was equal to the closing price of our Common
Stock on the date of investment, were issued by the Company and its wholly-owned subsidiaries Pharmaloz Manufacturing, Inc. and
Quigley Pharma, Inc. (collectively, the “Obligors”) and funded on December 11, 2015. We incurred loan origination costs
of $22,000 which was recorded as a reduction of the Notes and the origination costs are charged to interest expense over the term
of the loan. The Warrants have an exercise term equal to three years and are exercisable commencing on the date of issuance. The
fair value of the Warrants at the date of grant was $14,000 which is recorded as a reduction of the Notes and is charged to interest
expense over the term of the loan. At March 31, 2016, the $1.5 million Notes are reported net of $28,000 of the unamortized interest
for the loan origination costs and unamortized interest for the Warrants. At March 31, 2016, other current liabilities include
$56,000 for accrued interest under the terms of the Notes.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Notes are secured
by all of our tangible and intangible assets. The Notes bear interest at the rate of 12% per annum, payable semi-annually and the
principal is due and payable on June 15, 2017. The Notes may be pre-paid at any time prior to maturity without penalty. The effective
interest, inclusive of the Warrant and loan origination costs, is 14.3% per annum. For the three months ended March 31, 2016, we
charged to interest expense $52,000 in connection with the Notes.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
the issuance of the Notes, we entered into a security agreement with John E. Ligums, Jr. (an Investor and a shareholder in the
Company), as collateral agent for the Investors (the “Security Agreement”) to secure the timely payment and performance
in full of the Obligors’ obligations pursuant to the Notes. Under the Security Agreement, the Obligors grant to the Collateral
Agent, for the benefit of the Investors a lien upon and security interest in the property and assets listed as collateral in the
Security Agreement, including without limitation, all of the Obligors’ personal property, inventory, equipment, general intangibles,
cash and cash equivalents, and proceeds.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>  </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Godfrey Settlement Agreement</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2004,
we commenced an action against John C. Godfrey, Nancy Jane Godfrey, and Godfrey Science and Design, Inc. (together the “Godfreys”)
for injunctive relief regarding the ownership of the Cold-EEZE<sup>®</sup> trademark. The Godfreys subsequently asserted against
us counterclaims and sought monetary damages and injunctive and declaratory relief relative to the Cold-EEZE<sup>®</sup> trademark
and other intellectual property.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 20,
2012, we and the Godfreys, including the Estate of Nancy Jane Godfrey, entered into a Settlement Agreement and Mutual General Release
(the “Godfrey Settlement Agreement”), pursuant to which we resolved all disputes, including claims asserted by us and
counterclaims asserted against us in the action. At each of March 31, 2016 and December 31, 2015, other current liabilities include
$100,000, inclusive of accrued interest at the annual rate of 3.25%, for final installment payment due in December 2016 pursuant
to the terms of the Settlement Agreement.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 – Income Taxes</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31,
2015, we have net operating loss carry-forwards of approximately $44.5 million for federal purposes that will expire beginning
in Fiscal 2020 through 2034. Additionally, there are net operating loss carry-forwards of $21.9 million for state purposes that
will expire beginning in Fiscal 2020 through 2034. Until sufficient taxable income to offset the temporary timing differences attributable
to operations, and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling
the total deferred tax asset is being provided. As a consequence of the accumulated losses of the Company, we believe that this
allowance is required due to the uncertainty of realizing these tax benefits in the future.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7– Commitments and Contingencies
</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>PROPHASE LABS, INC. PROPHASE LABS,
INC. FOR THE BENEFIT OF PHUSION LABORATORIES, LLC vs. Phosphagenics, Inc., Phosphagenics, LTD and Phusion Laboratories, LLC as
a nominal defendant</u></i></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 17, 2014,
we initiated a demand for arbitration with the American Arbitration Association, case number 01-14-0001-7373. This demand for arbitration
pertains to our Phusion joint venture and the matter is against Phosphagenics, Inc. and Phosphagenics LTD (collectively known as
the “Phosphagenics Entities”). We have raised certain claims based upon the Phosphagenics Entities’ alleged breach
of a certain amended and restated license agreement for the exploitation of certain intellectual property and, separately, breach
of the Phusion joint venture operating agreement as between the Company and the Phosphagenics Entities. The Phosphagenics Entities
have made counter claims of breaches against the Company and Phusion. The arbitration hearing was held during December 2015 and
January 2016 and the evidentiary hearing is now concluded. Each of the parties submitted to the arbitrator their post-hearing briefs
on or before March 15, 2016. At this time while no prediction as to the outcome of this action can be made, we anticipate an arbitral
ruling will likely be rendered in or about June 2016 and we do not expect a material adverse outcome.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have estimated
future minimum obligations over the next five years, including the remainder of Fiscal 2016, as follows (in thousands):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal Year</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employment Contracts</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Godfrey Settlement Agreement</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Note</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 16%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 21%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">769</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">869</font></td>
<td style="width: 1%; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,025</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,525</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">512</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">512</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,306</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,906</font></td>
<td style="line-height: 115%"> </td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b></b></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 – Earnings (Loss) Per Share</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic earnings (loss) per
share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of
our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur
if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance
of Common Stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilize the treasury stock method
which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during
the period. Options and warrants outstanding to acquire shares of our Common Stock at March 31, 2016 and 2015 were 1,759,500 and
1,739,500, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the three months
ended March 31, 2016 and 2015, dilutive earnings (loss) per share is the same as basic earnings per share due to (i) the inclusion
of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive
effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended
March 31, 2016 and 2015, there were 209,559 and 358,411 Common Stock Equivalents, respectively, which were in the money, that were
excluded from the earnings (loss) per share computation as a consequence of their anti-dilutive effect.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation
of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing
operations, is as follows (in thousands, except per share amounts):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three Months Ended March 31, 2016</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three Months Ended March 31, 2015</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Loss</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">EPS</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Loss</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">EPS</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Basic</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="width: 28%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">loss per share</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,336</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,081</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,380</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,892</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.09</font></td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dilutives:</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"> </td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Diluted loss per share</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,336</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">17,081</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,380</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,892</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.09</font></td>
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The components
of inventory are as follows (in thousands):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2016</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2015</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 28%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,416</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 28%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,303</font></td>
<td style="width: 1%; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Work in process</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">299</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">530</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,357</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,498</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,072</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,331</font></td>
<td style="line-height: 115%"> </td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="margin: 0pt"></p>
10272000
11879000
1055000
1884000
4072000
4331000
2688000
4000000
13325000
14829000
3053000
2950000
4359000
4534000
604000
1036000
2193000
2508000
1562000
990000
1472000
1466000
1472000
1466000
13325000
14829000
-18155000
-16819000
56378000
56377000
13000
13000
17081
15892
107000
83000
6000
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 – Transactions Affecting
Stockholders’ Equity</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our authorized capital
stock consists of 50 million shares of Common Stock and 1 million shares of preferred stock, $.0005 par value (“Preferred
Stock”).</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock </i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 16, 2015,
our shareholders approved the change our state of incorporation from the State of Nevada to the State of Delaware pursuant to a
plan of conversion (“Conversion Plan”) and the filing of a certificate of incorporation in the State of Delaware. The
Preferred Stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of
March 31, 2016, no shares of Preferred Stock have been issued. Our board of directors has the full authority permitted by law to
establish, without further stockholder approval, one or more series and the number of shares constituting each such series and
to fix by resolution voting powers, preferences and relative, participating, optional and other special rights of each series of
Preferred Stock, and the qualifications, limitations or restrictions thereof, if any. Subject to the limitation on the total number
of shares of Preferred Stock that we have authority to issue under our certificate of incorporation, the board of directors is
also authorized to increase or decrease the number of shares of any series, subsequent to the issue of that series, but not below
the number of shares of such series then-outstanding. In case the number of shares of any series is so decreased, the shares constituting
such decrease will resume the status that they had prior to the adoption of the resolution originally fixing the number of shares
of such series. We may amend from time to time our certificate of incorporation and bylaws to increase the number of authorized
shares of Preferred Stock or Common Stock or to make other changes or additions.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stockholder Rights Plan</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 8,
1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right”
and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder
Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August
18, 2009 and (iii) June 18, 2014. The Rights Agreement, as amended and restated, provides that each Right entitles the stockholder
of record to purchase from the Company that number of shares of Common Stock having a combined market value equal to two times
the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public
announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of Common
Stock, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the
ownership of 15% or more of the outstanding shares of Common Stock (such person, the “acquirer”). The Rights Agreement
allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common
Stock without our Board of Directors declaring a dividend distribution.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The dividend has
the effect of diluting the acquirer by giving our other stockholders a 50% discount on our Common Stock’s current market
value for exercising the Rights. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial
ownership of the Company, a stockholder may exchange one Right for one share of Common Stock of the Company. The Rights Agreement,
as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement
an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise
be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms.
The expiration date of the Rights Agreement, as amended, is June 18, 2024.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity Line of Credit</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 30, 2015,
we entered into a new equity line of credit agreement (such arrangement, the “2015 Equity Line”) with Dutchess Opportunity
Fund II, LP (“Dutchess”). Pursuant to the 2015 Equity Line, Dutchess committed to purchase, subject to certain restrictions
and conditions, up to 3,200,000 shares of our Common Stock, over a period of 36 months from the effectiveness of the registration
statement registering the resale of shares purchased by Dutchess pursuant to the Investment Agreement.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may, at our discretion,
draw on the 2015 Equity Line from time to time, as and when we determine appropriate in accordance with the terms and conditions
of the 2015 Equity Line. The maximum number of shares that we are entitled to put to Dutchess in any one draw down notice shall
not exceed 500,000 shares with a purchase price calculated in accordance with the 2015 Equity Line. We may deliver a notice for
a subsequent put from time to time, following the one day pricing period for the prior put.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purchase price
shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Common Stock during the one trading
day immediately following our put notice. We have the right to withdraw all or any portion of any put, except that portion of the
put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set
forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales
for a specific put, Dutchess must remit such excess proceeds to us; however, in the event Dutchess receives less than a five percent
(5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on
the applicable closing date so Dutchess’s return will equal five percent (5%).</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are put restrictions
applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, we
are entitled to deliver another draw down notice. In addition, Dutchess will not be obligated to purchase shares if Dutchess’
total number of shares beneficially held at that time would exceed 4.99% of the number of shares of Common Stock as determined
in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw
on the facility unless there is an effective registration statement to cover the resale of the shares.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the
terms of the 2015 Equity Line, we are obligated to file one or more registrations statements with the SEC to register the resale
by Dutchess of the shares of Common Stock issued or issuable under the 2015 Equity Line. In addition, we are obligated to use all
commercially reasonable efforts to have the registration statement declared effective by the SEC within 90 days after the registration
statement is filed. On August 4, 2015, we filed a registration statement for the underlying shares of the 2015 Equity Line with
the SEC and the registration statement was declared effective by the SEC on August 21, 2015.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The sales of the
shares under the 2015 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance
upon Section 4(2) (or Regulation D promulgated thereunder). At March 31, 2016, we have 2,450,000 shares of our Common Stock available
for sale, at our discretion, under the terms of the 2015 Equity Line and covered pursuant to a registration statement.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The 2010 Equity Compensation Plan</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 5, 2010,
our stockholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by stockholders
on April 24, 2011 and further amended and approved by stockholders on May 6, 2013 (the “2010 Plan”). The 2010 Plan
provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 2.5 million shares,
including 900,000 shares that are authorized for issuance but unissued under a 1997 incentive stock option plan. No options were
granted under the 2010 Plan for the three months ended March 31, 2016 or 2015. There were no stock options exercised for the three
months ended March 31, 2016 or 2015. At March 31, 2016, there were 1,713,000 options outstanding under the 2010 Plan and 24,159
options available to be issued pursuant to the terms of the 2010 Plan.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The 2010 Directors’ Equity
Compensation Plan</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 5, 2010,
our stockholders approved the 2010 Directors’ Equity Compensation Plan which was subsequently amended and approved by stockholders
on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay
all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan
provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation
Plan is equal to 425,000. For the three months ended March 31, 2016 or 2015, no shares were granted to directors. At March 31,
2016, there were 147,808 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation
Plan.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 – Joint Venture </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2010,
we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware
corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (“Phusion”), a Delaware limited liability company,
entered into a Limited Liability Company Agreement (the “LLC Agreement”) of Phusion and additional related agreements
for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies
using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth
of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and
PSI each own a 50% membership interest in the Phusion joint venture.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the “Original
License Agreement”), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit
OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively,
the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up
license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds
with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 17, 2014,
we initiated a demand for arbitration with the American Arbitration Association, case number 01-14-0001-7373. The Phosphagenics
Entities (defined below) have made counter claims of breaches against the Company and Phusion (see Note 7). At March 31, 2016,
cash and cash equivalents includes $366,000 which is available to be used by Phusion to fund future product development initiatives.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited condensed
consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial
statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements
and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with
accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed
consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated
financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31,
2015. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated
results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the
three months ended March 31, 2016 are not necessarily indicative of operating results that may be achieved over the course of the
full year.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Seasonality of the Business</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our net sales are
derived principally from our OTC heath care and cold remedy products. Currently, our sales are influenced by and subject to fluctuations
in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity
of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold
rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher
levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products
during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer
demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production
scheduling, inventory management and marketing programs to optimize consumer purchases.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the three months
ended March 31, 2016 and 2015, our net sales were principally related to domestic markets.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Use of Estimates</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation
of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and
assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include
the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible
assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising.
When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales
Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These
estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant
at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments
on a quarterly basis. Actual results could differ from those estimates.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our primary product,
Cold-EEZE<sup>Ò </sup>cold remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically
proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns
and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii)
promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels
at major customers and third-party consumption data. In addition to Cold-EEZE<sup>®</sup> cold remedy lozenges, we market and
distribute a variety of Cold-EEZE<sup>®</sup> cold remedy QuickMelts<sup>®</sup>, a Cold-EEZE<sup>® </sup>cold remedy
Oral Spray, a Cold-EEZE<sup>Ò </sup>Natural Allergy Relief caplets and Cold-EEZE<sup>®</sup> Daytime and Nighttime Multi-Symptom
Relief in a liquid form. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement. Each of the
Cold-EEZE<sup>®</sup> cold remedy Oral Spray and QuickMelts<sup>®</sup> products, Cold-EEZE<sup>Ò </sup>Natural
Allergy Relief caplets, Cold-EEZE<sup>®</sup> liquid forms and organic lozenge products carry shelf-life expiration dates for
which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales
allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis,
and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences
that could affect the expected provisions relative to net sales for the period presented.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Cash Equivalents</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider all
highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents
include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the
short-term maturity of these investments.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Inventory Valuation </i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Inventory is valued
at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost
and the market value and appropriate valuation adjustments are established. At March 31, 2016 and December 31, 2015, the financial
statements include adjustments to reduce inventory for excess or obsolete inventory of $476,000 and $501,000, respectively. The
components of inventory are as follows (in thousands):</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2016</font></td>
<td style="text-align: center; line-height: 115%"> </td>
<td style="text-align: center; line-height: 115%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2015</font></td>
<td style="text-align: center; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 28%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,416</font></td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"> </td>
<td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 28%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,303</font></td>
<td style="width: 1%; line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Work in process</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">299</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">530</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,357</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,498</font></td>
<td style="line-height: 115%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,072</font></td>
<td style="line-height: 115%"> </td>
<td style="line-height: 115%"> </td>
<td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,331</font></td>
<td style="line-height: 115%"> </td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Property, Plant and Equipment</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property, plant
and equipment are recorded at cost. We use the straight-line method in computing depreciation for financial reporting purposes.
Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements -
ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures
– five years.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Concentration of Risks</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future revenues,
costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity
together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC
and other personal care products in order to compete on a national level and/or international level.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business is
subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC health care
and cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration
(“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial instruments
that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts
receivable.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain cash
and cash equivalents with certain major financial institutions. As of March 31, 2016, our cash balance was $2.5 million and our
bank balance was $2.5 million. Of the total bank balance, $752,000 was covered by federal depository insurance and $1.7 million
was uninsured at March 31, 2016.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Trade accounts receivable
potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate
purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s
financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large
national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit
risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other
conditions that may impact the timing and collectability of amounts due to us. As a consequence of an evaluation of our customer’s
financial condition, payment patterns, balance due to us and other factors, we did not offset our account receivable with an allowance
for bad debt at March 31, 2016 and December 31, 2015.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b> </p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Long-lived Assets</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We review our carrying
value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount
of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum
of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount,
if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based
on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future
cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value
utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing
costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition;
and general economic and business conditions, among other factors.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fair value is based
on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier
fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs
such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either
directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore
requiring an entity to develop its own assumptions.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Instruments
</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents,
accounts receivable, accounts payable, accrued expenses and notes payable are reflected in the Condensed Consolidated Financial
Statements at carrying value which approximates fair value.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Revenue Recognition</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales are recognized
at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts
and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns
and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer
and consumer demand when evaluating the adequacy of the sales returns and other allowances.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our return policy
accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their
designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns
must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due
to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns
for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue
a product provided that the customer will have the right to return only such items that it purchased directly from us. We will
not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept
return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers
who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the
customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product
only, also by way of an exchange. We do not have any significant product exchange history.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">  </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31,
2016 and December 31, 2015, we included a provision for sales allowances of $44,000 and $83,000, respectively, which are reported
as a reduction to sales and account receivables. Additionally, accrued advertising and other allowances as of March 31, 2016 included
(i) $1.5 million for estimated future sales returns and (ii) $445,000 for cooperative incentive promotion costs. As of December
31, 2015, accrued advertising and other allowances included (i) $1.4 million for estimated future sales returns and (ii) $786,000
million for cooperative incentive promotion costs.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Advertising and Incentive Promotions</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Advertising and
incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense
is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions
and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part
of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended March 31, 2016 and 2015 were
$3.1 million and $3.1 million, respectively. Included in prepaid expenses and other current assets was $120,000 and $854,000 at
March 31, 2016 and December 31, 2015, respectively, relating to prepaid advertising and promotion expenses.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Shipping and Handling </i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Product sales carry
shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all
cases, costs related to this revenue are recorded in cost of sales.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Stock Based Compensation</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We recognize all
share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements
based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model.
The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with
the vesting period.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock and stock
options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees
and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 3). Stock options are exercisable
during a period determined by us, but in no event later than ten years from the date granted. For the three months ended March
31, 2016 and 2015, we charged to operations $1,000 and $34,000, respectively, for share-based compensation expense for the aggregate
fair value of stock grants issued and vested stock options earned.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Research and Development</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs are charged to operations in the period incurred. Research and development costs for the three months ended March 31, 2016
and 2015 were $86,000 and $208,000, respectively. Research and development costs are principally related to new product development
initiatives and costs associated with our OTC health care and cold remedy products.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Income Taxes</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize the asset
and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of
events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally
consider all expected future events other than enactments of changes in the tax law or rates. Until we have sufficient taxable
income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant
and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 4).</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize a two-step
approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by
determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on
audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as
the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties
related to income taxes will be recorded as interest or administrative expense, respectively.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of our
continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not
recorded a liability for unrecognized tax benefits.</p>
<p style="margin: 0pt"></p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recently Issued Accounting Standards</i></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the
Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, “Revenue from Contracts with Customers”,
on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers
as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing
and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective
approach or cumulative effect adjustment approach to implement the standard. As amended by ASU No. 2015-14 issued in August 2015,
this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2017, with early adoption
permitted. We are currently assessing the impact of this update, and believe that its adoption will not have a material impact
on our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b> </b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2014,
the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”.<i>
</i>The amendments in this update state that in connection with preparing financial statements for each annual and interim reporting
period, an entity’s management should evaluate whether there are conditions or events that raise substantial doubt about
the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued
(or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in
this update are effective for the annual reporting period beginning after December 15, 2016 and for annual periods and interim
periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our
consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2015, the
FASB issued ASU No. 2015-11 “Simplifying the Measurement of Inventory” which requires an entity to measure inventory
balances at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged
for inventory measured using LIFO or the retail inventory method. The amendments in this update are effective for the annual period
ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently assessing the impact of
this update, and believe that its adoption on January 1, 2017 will not have a material impact on our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016,
the FASB issued ASU No. 2016-02, Leases. The new standard will require most leases to be recognized on the balance sheet which
will increase reported assets and liabilities. Lessor accounting remains substantially similar to current guidance. The new standard
is effective for annual and interim periods in fiscal years beginning after December 15, 2018, which for us is the first quarter
of fiscal 2019 and mandates a modified retrospective transition method. We are currently assessing the impact of this update, and
believe that its adoption will not have a material impact on our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2016, the
FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects
of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory
tax withholding requirements, as well as classification in the statement of cash flows. ASU No. 2016-09 is effective for fiscal
years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for financial
statements that have not already been issued. We are currently assessing the impact that this ASU will have on our consolidated
financial position, results of operation and cash flows.</p>
<p style="margin: 0pt"></p>
1500000
22000
1759500
1739500
209559
358411
120000
854000
44500000
21900000